Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor

Lancet

Volumn 360, Issue 9344, 2002, Pages 1478-1480

  Dieckgraefe, Brian K ^a   Korzenik, Joshua R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD CELL COUNT; BONE PAIN; BREATHING DISORDER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; EOSINOPHIL; ERYTHEMA; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NECK PAIN; NEUTROPHIL; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REMISSION; SELF INJECTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037048904     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11437-1     Document Type: Article

References (4)

1. Korzenik J.R., Dieckgraefe B.K. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci. 45:2000;1121-1129.
2. Best W.R., Becktel J.M., Singleton J.W., Kern F. Jr. Development of a Crohn's disease activity index. Gastroenterology. 70:1976;439-444.
3. Irvine E.J., Feagan B., Rochon J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 106:1994;287-296.
4. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 411:2001;603-606.